tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
PremiumRatingsNeurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
27d ago
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
Premium
The Fly
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
27d ago
Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
Premium
The Fly
Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
2M ago
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
PremiumCompany AnnouncementsNeurogene Advances NGN-401 Gene Therapy for Rett Syndrome
3M ago
NGNE Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
NGNE Upcoming Earnings Report: What to Expect?
3M ago
Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
Premium
Ratings
Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
4M ago
Neurogene says on track to share updated clinical efficacy and safety data
PremiumThe FlyNeurogene says on track to share updated clinical efficacy and safety data
4M ago
Neurogene announces registrational trial design for Embolden study of NGN-401
Premium
The Fly
Neurogene announces registrational trial design for Embolden study of NGN-401
4M ago
Craig-Hallum bullish on Neurogene, initiates with a Buy
Premium
The Fly
Craig-Hallum bullish on Neurogene, initiates with a Buy
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100